Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location

Cancer Immunology, Immunotherapy

Volumn 56, Issue 7, 2007, Pages 1119-1131

  Kakinuma, Takashi ^b   Nadiminti, Hari ^b   Lonsdorf, Anke S ^b   Murakami, Takashi ^b   Perez, Bradford A ^b   Kobayashi, Hisataka ^b   Finkelstein, Steven E ^b   Pothiawala, Gulnar ^a   Belkaid, Yasmine ^a   Hwang, Sam T ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD4; Regulatory T cells; Tumorigenesis

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LUCIFERASE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; EAR; FEMALE; FOOT PAD; IMMUNE RESPONSE; INJECTION; INOCULATION; KNOCKOUT GENE; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 34247642343     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0253-4     Document Type: Article

References (32)

1. Antony PA, Restifo NP (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202-206
2. Bashford E, Murray J, Haaland M (1908) Resistance and suceptibility to inoculated cancer. In: Bashford E (ed) Third scientific report on the investigations of the imperial cancer research fund. Taylor & Francis, London pp 359-397
3. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA et al (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194:1497-1506
4. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507
5. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008
6. Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med 193:F23-F26
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
8. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623-3633
9. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
10. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373
11. Ehrlich P (1906) Collected studies on immunity. Wiley, London
12. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nature (New Biol) 242:148-149
13. Fontenot JD, Rudensky AY (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6:331-337
14. Franco M, Bustuoabad OD, di Gianni PD, Goldman A, Pasqualini CD, Ruggiero RA (1996) A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. Br J Cancer 74:178-186
15. Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA et al (2003) Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 50:758-766
16. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW (2003) Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res 63:271-276
17. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685
18. Ljunggren HG, Karre K (1985) Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162:1745-1759
19. Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO et al (2003) Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 198:1337-1347
20. Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M et al (2004) In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 13:613-620
21. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-1064
22. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133
23. O'Reilly M, Rosenthal R, Sage E, Smith S, Holmgren L, Moses M et al (1993) The suppression of tumor metastases by a primary tumor. Surg Forum 44:474-478
24. Ribas A, Timmerman JM, Butterfield LH, Economou JS (2003) Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58-61
25. Rosenberg SA (2004) Shedding light on immunotherapy for cancer. N Engl J Med 350:1461-1463
26. Saeki H, Moore AM, Brown MJ, Hwang ST (1999) Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 162:2472-2475
27. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218
28. Sugarbaker E, Thornthwaite J, Ketcham A (1977) Inhibitor effect of a primary tumor on metastasis. In: Day S et al (eds) Progress in cancer research and therapy. Raven, New York pp 227-240
29. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832
30. Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142:3714-3725
31. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200:771-782
32. Wiley H, Gonzalez EB, Maki W, Wu M, Hwang ST (2001) Expression of CC chemokine receptor-7 (CCR7) and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93:1638-1643